• 1
    Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone. 2001;4:1723.
  • 2
    Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol [serial online]. 2005;4:9.
  • 3
    Privratsky JR, Wold LE, Sowers JR. et al. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003;42:206212.
  • 4
    Lind L, Andersson PE, Andren B. et al. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens. 1995;13:433438.
  • 5
    Hayden MR, Tyagi SC. Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus and congestive heart failure. Med Sci Monit. 2003;9:SR35SR52.
  • 6
    Grundy SM, Benjamin IJ, Burke GL. et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:11341146.
  • 7
    Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol. 2001;1:181193.
  • 8
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:10531059.
  • 9
    Ludwig J, Viggiano TR, McGill DB. et al. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434438.
  • 10
    Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005; [Epub ahead of print].
  • 11
    Marchesini G, Brizi M, Bianchi G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:18441850.
  • 12
    Pagano G, Pacini G, Musso G. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367372.
  • 13
    Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353358.
  • 14
    Den Boer M, Voshol PJ, Kuipers F, et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Tromb Vasc Biol. 2004;24:644649.
  • 15
    Hayden MR, Tyagi SC. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol [serial online]. 2004;3:1.
  • 16
    Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:20322038.
  • 17
    Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471474.
  • 18
    Camejo G, Olsson U, Hurt-Camejo E, et al. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl. 2002;3:39.
  • 19
    Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Tromb Vasc Biol. 2000;20:11771178.
  • 20
    Kolodgie FD, Burke AP, Wight TN, et al. The accumulation of specific types of proteoglycan in eroded plaques: a role in coronary thrombosis in the absence of rupture. Curr Opin Lipidol. 2004;15:575582.
  • 21
    Hayden MR, Tyagi SC. Intimal redox stress: accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol [serial online]. 2002;1:3.
  • 22
    Hayden MR, Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP. 2002;3:86108.
  • 23
    Tikellis C, Wookey PJ, Candido R. et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004;53:989997.
  • 24
    Butler AE, Janson J, Soeller WC. et al. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52:23042314.
  • 25
    Hayden MR, Tyagi SC, Kerklo MM. et al. Type 2 diabetes mellitus as a conformational disease. JOP. 2005;6:287302.
  • 26
    Lin CY, Gurlo T, Haataja L. et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab. 2005;90:66786686.
  • 27
    Zhao HL, Lai FM, Tong PC. et al. Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes. 2003;52:27592766.
  • 28
    Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. JAMA. 2003;290:13711376.
  • 29
    Hayden MR, Tyagi SC. Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit. 2004;10:RA291RA307.
  • 30
    Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med. 2002;346:19992001.
  • 31
    Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab. 2002;3:159173.
  • 32
    Stuhlinger MC, Abbasi F, Chu JW. et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:14201426.
  • 33
    Nash DT. Insulin resistance, ADMA levels, and cardiovascular disease. JAMA. 2002;287:14511452.
  • 34
    Duplain H, Burcelin R, Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342345.
  • 35
    Veldman BA, Spiering W, Doevendans PA. et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. J Hypertens. 2002;20:20232027.
  • 36
    Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol. 2005;25:553569.
  • 37
    Chen J, Muntner P, Hamm LL. et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167174.
  • 38
    Bakris GL, Sowers JR. Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. Curr Diab Rep. 2002;2:258262.